A phase I multiple ascending dose (MAD) study of SAGE-217 in healthy volunteers

Trial Profile

A phase I multiple ascending dose (MAD) study of SAGE-217 in healthy volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Dravet syndrome; Rett syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Apr 2017 Results assessing safety and tolerability presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of two phase 1 studies assessing pharmacokinetics of SAGE-217 presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 19 Apr 2017 Data from this trial will be presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, according to a Sage Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top